Skip to content

Clinical observation for bushenshugan decoction in the treatment of decreased ovarian function patients with 'kidney deficiency and liver stagnation zhen'

Clinical observation for bushenshugan decoction in the treatment of decreased ovarian function patients with 'kidney deficiency and liver stagnation zhen'

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026239
Enrollment
Unknown
Registered
2019-09-28
Start date
2019-10-16
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diminished ovarian reserve

Interventions

Sponsors

Dongzhimen Hospital of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Meet the Western medicine diagnostic criteria of ovarian reserve function decline; 2. In line with TCM syndrome differentiation of kidney deficiency and liver stagnation syndrome; 3. Aged 18 to 40 years old; 4. Voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Female in gestation and lactation; 2. Primary amenorrhea or secondary amenorrhea caused by ovarian resistance syndrome, abnormal reproductive tract development, polycystic ovary syndrome, chocolate cyst of ovary, central nervous system tumor, functional hypothalamic amenorrhea, complete androgen insensitivity syndrome, Asherman syndrome; 3. Decreased ovarian reserve caused by iatrogenic factors; 4. Patients with severe primary diseases such as heart, liver and renal insufficiency, hematopoietic system and immune system; 5. Allergic to a variety of medicines, or known to be allergic to the prescribed medicines; 6. Suffering from any serious psychological or mental abnormality and being unable to follow the procedures and specifications of clinical trials; 7. The researchers did not consider it appropriate for patients to participate in clinical observation.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;FSH;FSH/LH;LH;E2;Ovarian size;TCM score;Kupperman Index;AFC;

Countries

China

Contacts

Public ContactYanfeng Liu

Dongzhimen Hospital of Beijing University of Chinese Medicine

dongzhimen3@163.com+86 010-84013157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026